Tag: Vaccines
NIH Trial Underway for Universal Flu Vaccine
Phase 1 trial testing both intranasal and intramuscular administration
Biden Administration May Back Second Booster Shots for All Adults
Expanding eligibility requirements for a fourth dose of the vaccine would require regulatory approval
Infant Hospitalization for COVID-19 Reduced With Maternal Vaccination
Effectiveness of maternal vaccination against COVID-19 hospitalization in infants 80 percent during delta, 38 percent during omicron
Adverse Reactions to BNT162b2 Mild, Moderate for 5- to 11-Year-Olds
Based on data from three U.S. safety monitoring systems, adverse events were mild-to-moderate, and myocarditis occurred rarely
COVID-19 Vaccination Greatly Reduced Morbidity, Mortality Burden in U.S.
Vaccination estimated to have prevented 52, 56, and 58 percent of expected infections, hospitalizations, deaths in adults from Sept. 1 to 30, 2021
Provider Availability Linked to COVID-19 Vaccine Uptake in Children
Vaccination coverage for children aged 5 to 11 higher in counties with at least one active COVID-19 vaccine provider versus no provider
Vaccination Protects Overweight, Obese Against Severe COVID-19
Protection against severe COVID-19 similar for those with overweight, obesity versus healthy weight; lower protection seen for underweight
FDA Tells Vaccine Makers to Update Boosters to Target Omicron Subvariants
Pfizer and Moderna are expected to start producing reformulated doses this summer
U.S. Orders 105 Million More Pfizer Shots for Fall Booster Campaign
Both Pfizer and Moderna have reported positive results with updated vaccines that target the omicron variant
Two Doses of BNT162b2 Moderately Effective for 5- to 11-Year-Olds
Moderate effectiveness against documented infection and symptomatic COVID-19 for those vaccinated on or after Nov. 23, 2021
